Tryptamine Therapeutics Limited
TYPTF
$0.02
$0.007.14%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.12% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.12% | -- | |||
| Cost of Revenue | 2.12% | -66.62% | |||
| Gross Profit | 2.12% | 152.11% | |||
| SG&A Expenses | 2.12% | -6.26% | |||
| Depreciation & Amortization | 1.87% | 62.12% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.11% | -33.00% | |||
| Operating Income | -2.11% | 71.37% | |||
| Income Before Tax | -2.12% | 68.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.12% | 68.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.12% | 68.77% | |||
| EBIT | -2.11% | 71.37% | |||
| EBITDA | -2.11% | 72.06% | |||
| EPS Basic | 0.00% | 72.73% | |||
| Normalized Basic EPS | 0.00% | 85.71% | |||
| EPS Diluted | 0.00% | 72.73% | |||
| Normalized Diluted EPS | 0.00% | 85.71% | |||
| Average Basic Shares Outstanding | 0.00% | 41.28% | |||
| Average Diluted Shares Outstanding | 0.00% | 41.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||